Sun Pharmaceutical Industries is currently trading at Rs 1045.00, up by 7.70 points or 0.74% from its previous closing of Rs 1037.30 on the BSE.
The scrip opened at Rs. 1045.10 and has touched a high and low of Rs. 1066.40 and Rs. 1038.95 respectively. So far 155651 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.70 on 07-Apr-2015 and a 52 week low of Rs. 572.15 on 22-May-2014.
Last one week high and low of the scrip stood at Rs. 1160.10 and Rs. 1028.00 respectively. The current market cap of the company is Rs. 251199.00 crore.
The promoters holding in the company stood at 63.65 % while Institutions and Non-Institutions held 26.55 % and 9.80 % respectively.
Sun Pharmaceutical Industries’ and certain of its subsidiaries have executed settlement agreement with ‘The Medicines Company, USA’ settling the lawsuit filed in the United States against the company and its subsidiaries regarding submission of an Abbreviated New Drug Application (ANDA) by one of subsidiaries, for a generic version of Angiomax, Bivaliruding injection. This product is a direct thrombin inhibitor indicated for use as an anticoagulant.
Under the terms of the settlement agreement, the company’s subsidiary is entitled to launch its version of generic Angiomax in the United States on June 30, 2019 or earlier under certain limited circumstances.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: